Virtus ETF Advisers’s Neurocrine Biosciences NBIX Stock Holding History

Virtus ETF Advisers’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$340K	Hold	2,584	–	–	0.16%	161
2025 Q4	$366K	Hold	2,584	–	–	0.17%	147
2025 Q3	$363K	Hold	2,584	–	–	0.2%	136
2025 Q2	$325K	Hold	2,584	–	–	0.2%	138
2025 Q1	$286K	Sell	2,584 -174	-6%	-$22K	0.19%	158
2024 Q4	$376K	Buy	2,758 +341	+14%	+$42.2K	0.15%	190
2024 Q3	$278K	Hold	2,417	–	–	0.13%	234
2024 Q2	$333K	Sell	2,417 -723	-23%	-$99.2K	0.16%	209
2024 Q1	$433K	Buy	3,140 +452	+17%	+$61.7K	0.23%	187
2023 Q4	$354K	Sell	2,688 -539	-17%	-$62K	0.22%	185
2023 Q3	$363K	Sell	3,227 -420	-12%	-$44.2K	0.22%	187
2023 Q2	$344K	Buy	3,647 +1,062	+41%	+$104K	0.2%	159
2023 Q1	$262K	Buy	2,585 +48	+2%	+$5K	0.14%	272
2022 Q4	$303K	Sell	2,537 -45	-2%	-$5.27K	0.16%	262
2022 Q3	$274K	Buy	2,582 +38	+1%	+$3.86K	0.11%	284
2022 Q2	$248K	Sell	2,544 -1,953	-43%	-$180K	0.09%	299
2022 Q1	$422K	Hold	4,497	–	–	0.19%	149
2021 Q4	$383K	Sell	4,497 -97	-2%	-$8.92K	0.14%	167
2021 Q3	$441K	Sell	4,594 -418	-8%	-$39.5K	0.19%	157
2021 Q2	$488K	Sell	5,012 -1,680	-25%	-$161K	0.2%	155
2021 Q1	$651K	Buy	6,692 +180	+3%	+$18.9K	0.28%	116
2020 Q4	$624K	Buy	6,512 +1,421	+28%	+$137K	0.26%	101
2020 Q3	$490K	Buy	5,091 +284	+6%	+$32.9K	0.26%	140
2020 Q2	$587K	Sell	4,807 -515	-10%	-$56.9K	0.28%	122
2020 Q1	$461K	Sell	5,322 -449	-8%	-$43.9K	0.19%	178
2019 Q4	$620K	Sell	5,771 -2,479	-30%	-$260K	0.1%	184
2019 Q3	$743K	Sell	8,250 -1,396	-14%	-$130K	0.15%	158
2019 Q2	$814K	Sell	9,646 -1,025	-10%	-$84.2K	0.17%	181
2019 Q1	$940K	Buy	10,671 +2,386	+29%	+$199K	2%	11
2018 Q4	$592K	Buy	8,285 +462	+6%	+$44.3K	0.1%	47
2018 Q3	$962K	Buy	7,823 +527	+7%	+$59.8K	0.1%	54
2018 Q2	$717K	Sell	7,296 -5,603	-43%	-$502K	0.63%	92
2018 Q1	$1.07M	Sell	12,899 -753	-6%	-$63.6K	0.93%	31
2017 Q4	$1.06M	Sell	13,652 -9,899	-42%	-$675K	1.33%	9
2017 Q3	$1.44M	Hold	23,551	–	–	0.19%	36
2017 Q2	$1.08M	Buy	23,551 +17,076	+264%	+$828K	0.16%	56
2017 Q1	$280K	Buy	6,475 +621	+11%	+$26.6K	0.05%	145
2016 Q4	$227K	Buy	5,854 +530	+10%	+$24K	0.07%	162
2016 Q3	$270K	Hold	5,324	–	–	0.13%	112
2016 Q2	$242K	Buy	5,324 +564	+12%	+$26K	0.18%	99
2016 Q1	$188K	Buy	+4,760	New	+$189K	0.26%	94

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtus ETF Advisers's NBIX Position: Q1 2026 in Review

Virtus ETF Advisers held its Neurocrine Biosciences (NBIX) position steady in Q1 2026 at 2,584 shares worth $340K. The position accounts for 0.16% of the portfolio, ranked #161.

Virtus ETF Advisers first reported a position in NBIX in Q1 2016 and has held it in 41 quarters since. The position peaked at $1.44M in Q3 2017. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Virtus ETF Advisers held 2,584 shares of Neurocrine Biosciences worth $340K as of Q1 2026.
Virtus ETF Advisers left its Neurocrine Biosciences share count unchanged in Q1 2026.
Neurocrine Biosciences made up 0.16% of Virtus ETF Advisers's portfolio in Q1 2026, its #161 holding.
Virtus ETF Advisers first reported a position in Neurocrine Biosciences in Q1 2016 and has held it in 41 quarters since.
Virtus ETF Advisers's Neurocrine Biosciences position peaked at $1.44M in Q3 2017.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Virtus ETF Advisers's 13F filing for Q1 2026, filed 14 May 2026.